The MonumenTAL-2 study is discussed by Rafael Fonesca, MD.
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
The phase 1/2 MonumenTAL-2 study evaluated the combination of the anti-GPRC5D antibody talquetamab and the immunomodulatory drug pomalidomide in relapsed/refractory multiple myeloma. Patients had received a median of 3 prior lines of treatment. Pomalidomide was started at the lower dose of 2 mg (range, 2-4 mg) to manage myelosuppression risks. Stepwise talquetamab dose increases also occurred. Despite some dose reductions, adverse reactions were consistent with each agent’s known single-agent toxicities.
The overall response rate was 94% with talquetamab 0.4 mg/kg weekly, on par with other antibody combinations like talquetamab plus teclistamab. Deep responses occurred, with 44% stringent complete response rate and 63% complete response rate in heavily pretreated patients. Although next steps for talquetamab are still unknown, this data supports continued development of GPRC5D-targeting combinations in myeloma.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More